Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LRMR Stock Forecast 2026-2027
$3.10
Current Price
$322.04M
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LRMR Price Targets
+738.7%
To High Target of $26.00
+319.4%
To Median Target of $13.00
+125.8%
To Low Target of $7.00
LRMR Price Momentum
-6.1%
1 Week Change
-21.9%
1 Month Change
+16.5%
1 Year Change
-18.6%
Year-to-Date Change
-51.7%
From 52W High of $6.42
+39.6%
From 52W Low of $2.22
📊 TOP ANALYST CALLS
Did LRMR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Larimar is one of their latest high-conviction picks.
Latest LRMR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, LRMR has a bullish consensus with a median price target of $13.00 (ranging from $7.00 to $26.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $3.10, the median forecast implies a 319.4% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LRMR Analyst Ratings
10
Buy
0
Hold
0
Sell
LRMR Price Target Range
Low
$7.00
Average
$13.00
High
$26.00
Current: $3.10
Latest LRMR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LRMR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 27, 2026 | JP Morgan | Tessa Romero | Overweight | Initiates | $9.00 |
| May 18, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Mar 20, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Mar 3, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Feb 25, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 25, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Oct 2, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Sep 30, 2025 | Wedbush | Outperform | Maintains | $N/A | |
| Sep 30, 2025 | Baird | Outperform | Maintains | $N/A | |
| Aug 19, 2025 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Aug 15, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jun 25, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Jun 24, 2025 | Wedbush | Outperform | Maintains | $N/A | |
| Jun 24, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Mar 25, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Mar 25, 2025 | Baird | Outperform | Maintains | $N/A | |
| Mar 25, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 29, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Jan 24, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Larimar Therapeutics Inc. (LRMR) Competitors
The following stocks are similar to Larimar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Larimar Therapeutics Inc. (LRMR) Financial Data
Larimar Therapeutics Inc. has a market capitalization of $322.04M with a P/E ratio of -1.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -109.8%.
Valuation Metrics
Market Cap
$322.04M
Enterprise Value
$126.98M
P/E Ratio
-1.4x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+61.9%
Current Ratio
4.3x
Debt/Equity
2.4x
ROE
-109.8%
ROA
-56.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Larimar Therapeutics Inc. (LRMR) Business Model
About Larimar Therapeutics Inc.
What They Do
Develops treatments for rare diseases using peptides.
Business Model
Larimar Therapeutics operates as a clinical-stage biotechnology company that leverages its proprietary cell-penetrating peptide technology to create therapies for rare diseases. The company primarily generates revenue by advancing its lead product candidate, nomlabofusp, through clinical trials to ultimately seek regulatory approval, which could lead to commercialization and sales.
Additional Information
The company's lead candidate is currently in Phase 2 clinical trials for Friedreich’s ataxia, showing promising results in restoring frataxin protein levels. Larimar Therapeutics is also exploring the application of its technology platform to other rare diseases characterized by intracellular protein deficiencies, positioning itself as a key player in the biotechnology sector focused on unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
71
CEO
Dr. Carole S. Ben-Maimon M.D.
Country
United States
IPO Year
2014
Website
www.larimartx.comLarimar Therapeutics Inc. (LRMR) Latest News & Analysis
Latest News
Quick Summary
Larimar Therapeutics plans to submit a rolling BLA for accelerated approval by June 2026, with final modules due in H2 2026. As of March 31, 2026, the company had $200.4 million in cash.
Why It Matters
Larimar Therapeutics is advancing its drug development with a BLA submission planned for 2026, backed by significant cash reserves, indicating potential growth and risk for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Larimar Therapeutics (Nasdaq: LRMR) announced the publication of a study on Nomlabofusp treatment in the journal Clinical and Translational Science, supporting surrogate tissue sampling for frataxin levels.
Why It Matters
The publication in a reputable journal validates Larimar's research, potentially enhancing credibility and attracting interest, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company reports pro forma cash and marketable securities of $244.5 million, including $136.9 million as of December 31, 2025, plus $107.6 million from a February 2026 public offering.
Why It Matters
The increase in cash and marketable securities indicates stronger liquidity, enhancing the company's financial stability and capacity for growth or investments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
2 Breakout Stocks to Buy Immediately
3 months ago
Quick Summary
Tom Yeung recalls his visit to the observatory at One World Trade Center, the tallest building in the Western Hemisphere, which opened in 2015.
Why It Matters
The mention of One World Trade Center may indicate a focus on tourism and real estate trends in New York, potentially impacting related investments in hospitality and local businesses.
Source: InvestorPlace
Market Sentiment:
Positive
Quick Summary
Larimar Therapeutics (Nasdaq: LRMR) will present and hold 1x1 investor meetings at upcoming conferences in Miami Beach, FL, focusing on treatments for complex rare diseases.
Why It Matters
Larimar's management engaging in investor meetings signals active communication and potential investor interest, which may enhance confidence and influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Larimar's stock rose 55% in a month following the FDA's breakthrough therapy designation for its drug nomlabofusp, indicating a potential accelerated approval process.
Why It Matters
Larimar's stock surge reflects investor optimism over accelerated drug approval, potentially leading to quicker revenue and market entry, enhancing future growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About LRMR Stock
What is Larimar Therapeutics Inc.'s (LRMR) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Larimar Therapeutics Inc. (LRMR) has a median price target of $13.00. The highest price target is $26.00 and the lowest is $7.00.
Is LRMR stock a good investment in 2026?
According to current analyst ratings, LRMR has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LRMR stock?
Wall Street analysts predict LRMR stock could reach $13.00 in the next 12 months. This represents a 319.4% increase from the current price of $3.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Larimar Therapeutics Inc.'s business model?
Larimar Therapeutics operates as a clinical-stage biotechnology company that leverages its proprietary cell-penetrating peptide technology to create therapies for rare diseases. The company primarily generates revenue by advancing its lead product candidate, nomlabofusp, through clinical trials to ultimately seek regulatory approval, which could lead to commercialization and sales.
What is the highest forecasted price for LRMR Larimar Therapeutics Inc.?
The highest price target for LRMR is $26.00 from at , which represents a 738.7% increase from the current price of $3.10.
What is the lowest forecasted price for LRMR Larimar Therapeutics Inc.?
The lowest price target for LRMR is $7.00 from at , which represents a 125.8% increase from the current price of $3.10.
What is the overall LRMR consensus from analysts for Larimar Therapeutics Inc.?
The overall analyst consensus for LRMR is bullish. Out of 2 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are LRMR stock price projections?
Stock price projections, including those for Larimar Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 3:13 AM UTC